Apple Inc vs Novo Nordisk A/S — how do they compare? Apple Inc trades at $303.87 (market cap $4.45T), while Novo Nordisk A/S trades at $45.97 (market cap $207.85B). The key difference: Apple Inc is far larger — about 21.4× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| AAPL | NVO | |
|---|---|---|
Market Cap | $4.45T | $207.85B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $63.98 |
52-Week Low | $224.90 | $35.29 |
Enterprise Value | $4.47T | $222.55B |
Dividend Yield | 0.35% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and near-term support at $306. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union disputes and potential Q3 earnings pressure.
Outlook remains positive driven by AI opportunities and a massive device ecosystem, but risks include weaker iPhone sales, regulatory scrutiny, and union tensions. The stock offers growth potential with solid cash flow, yet investors should weigh near-term headwinds against long-term strengths.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →